Insulin Detemir (Levemir)

A recombinant long-acting insulin and hypoglycemic agent in which a MYRISTIC ACID is conjugated to a LYSINE at position B29. It is used to manage BLOOD GLUCOSE levels in patients with DIABETES MELLITUS.

Also Known As:

Levemir; 12C-Lys(B29)-DB30I; B29-tetradecanoyl-Lys-B30-des-Ala-insulin; Basal Insulin Detemir; Des-(B30)-insulin, Lys(B29)-tetradecanoyl; Insulin, Tetradecanoyl-Lys(B29)-des-Ala(B30); Insulin, Tetradecanoyllysyl(B29)-desalanyl(B30); NN 304; NN-304; NN304; B29 tetradecanoyl Lys B30 des Ala insulin; Detemir, Basal Insulin; Detemir, Insulin; Insulin Detemir, Basal

Networked: 438 relevant articles (53 outcomes, 197 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Valentine, William J: 8 articles (01/2018 - 11/2004)
2.	SOLVE Study Group: 8 articles (03/2016 - 07/2012)
3.	Shetty, Raman: 8 articles (09/2014 - 04/2011)
4.	Mathiesen, Elisabeth R: 7 articles (01/2021 - 09/2011)
5.	Aagren, Mark: 7 articles (12/2011 - 01/2008)
6.	Damm, Peter: 6 articles (01/2021 - 09/2011)
7.	Home, Philip: 6 articles (03/2015 - 05/2004)
8.	Svendsen, Anne Louise: 6 articles (07/2014 - 09/2011)
9.	Haddad, Jihad: 6 articles (12/2013 - 05/2010)
10.	Clauson, Per: 6 articles (01/2013 - 06/2006)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 09/01/2013 - "People with type 2 diabetes in poor glycaemic control starting treatment with insulin detemir reported significant improvements in glycaemic control with improved treatment tolerability, irrespective of prior treatment and geographical region, after 24 weeks." 06/01/2014 - "This sub-analysis of the A1chieve study aimed to examine the safety and efficacy of insulin detemir (IDet) initiation over 24 weeks in relation to baseline body mass index (BMI) in people with type 2 diabetes mellitus (T2DM). " 12/01/2013 - "This study aimed at determining the clinical safety and efficacy of insulin detemir (IDet) in combination with oral anti-diabetic drugs (OADs) in type 2 diabetes (T2D) patients from four Near East Countries (Israel, Jordan, Pakistan and Lebanon). " 04/01/2013 - "To determine the safety and efficacy of insulin detemir in Indonesian patients with type 2 diabetes (T2D) as a sub-analysis of the 24-week, prospective, multinational, non-interventional A₁chieve study. " 12/01/2012 - "Evaluate the safety and efficacy of once-daily insulin detemir initiated in routine clinical practice in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycaemic agents (OHAs). "
2.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 08/01/2013 - "This 26-wk observational study in children and adolescents with type 1 diabetes (T1D) in Sweden investigated the safety and efficacy of insulin detemir (IDet) in newly diagnosed (ND) patients and those with established diabetes (ED) switching to IDet. " 08/01/2013 - "A multicenter observational safety study in Swedish children and adolescents using insulin detemir for the treatment of type 1 diabetes." 03/01/2009 - "[Insulin detemir in the predictive study: results in patients with type 1 diabetes in the Belgian cohort]." 08/21/2004 - "Insulin detemir has a very low variability in absorption and also seems to reduce the risk of nocturnal hypoglycaemia in diabetes type 1. More studies are, however, needed. " 05/01/2013 - "To assess the efficacy and safety of insulin detemir administered once vs. twice daily in children and adolescents with type 1 diabetes mellitus. "
3.	Hypoglycemia (Reactive Hypoglycemia) 05/01/2014 - "The aim of the present study was to identify demographic and treatment factors that were predictive of hypoglycemia in a large cohort of type 2 diabetic patients initiating insulin detemir. " 11/01/2011 - "The safety results of this study showed that 26 weeks of treatment with insulin detemir was associated with a very low rate of SADRs (only 14 events), which mainly consisted of hypoglycemia (78%, of which 42% were major hypoglycemia). " 12/01/2017 - "Impact of Insulin Detemir Administration Time on Hypoglycemia Rates in Hospitalized Patients." 04/01/2013 - "Insulin detemir was further decreased to 10 units without further symptoms of hypoglycemia for the remainder of the H. pylori treatment. " 04/01/2013 - "Insulin detemir was decreased to 15 units and hypoglycemia reoccurred. "
4.	Weight Gain 09/01/2004 - "Studies of insulin detemir in basal-bolus regimens in type I and type II diabetes have shown significantly less weight gain compared with NPH. " 01/01/2017 - "Our results confirmed that insulin detemir did not lead to weight gain. " 01/01/2013 - "As no significant differences in HbA1c were observed between the two treatment arms, the model was based on significant differences in favour of insulin detemir in frequency of hypoglycaemia (Rate-Ratio = 0.52; CI = 0.44-0.61) and weight gain (Δ = 0.9 kg). " 04/01/2010 - "Introduction of insulin detemir, at the appropriate time, can help empower patients to reach glycaemic targets, with a reduced risk of hypoglycaemia and less weight gain." 04/01/2010 - "Insulin detemir has demonstrated the additional advantage of less weight gain. "
5.	Body Weight (Weight, Body) 05/01/2007 - "These data confirm the short-term safety and efficacy of insulin detemir +/- OADs in a real-world scenario and support the findings of randomized controlled clinical trials with insulin detemir, including its limited effects on body weight." 03/01/2003 - "Body weight was significantly lower with insulin detemir at the end of the trial (P < 0.001). " 11/01/2017 - "Central effects of insulin detemir on feeding, body weight, and metabolism in rats." 01/01/2012 - "Treatment with insulin detemir for 6 months resulted in substantial benefits, including reduced HbA(1c), FPG and body weight, and improvements in nocturnal quality of life, without increasing hypoglycaemia." 07/04/2011 - "Insulin detemir attenuates food intake, body weight gain and fat mass gain in diet-induced obese Sprague-Dawley rats."

Related Drugs and Biologics

1.	Isophane Insulin (NPH Insulin)
2.	Insulin (Novolin)
3.	Insulin Glargine (Lantus)
4.	Hypoglycemic Agents (Hypoglycemics)
5.	Glucose (Dextrose)
6.	Insulin Detemir (Levemir)
7.	Protamines (Protamine Sulfate)
8.	Blood Glucose (Blood Sugar)
9.	Insulins
10.	insulin degludec

Related Therapies and Procedures

1.	Glycemic Control
2.	Therapeutics
3.	Injections
4.	Subcutaneous Injections
5.	Duration of Therapy